The Case For CAR-T Grows As Responses Hold Up Longer Term
Executive Summary
Novartis and Gilead longer-term data show largely steady response and survival rates, shoring up the clinical and commercial case for their products and justifying continued investment in T-cell therapies. The CAR-T pioneers discuss their progress, including with allogeneic platforms, with Scrip at ASH.
You may also be interested in...
Bispecifics Could Be A Threat To CAR-Ts
T-cell-engaging bispecific antibodies emerged at ASH as viable competitors for autologous T-cell therapies, but while their off-the-shelf availability is intriguing, it may be too early to say if their safety and efficacy beats CAR-Ts.
Bispecifics Could Be A Threat To CAR-Ts, But Efficacy May Trump Convenience
T-cell-engaging bispecific antibodies emerged at ASH as viable competitors for autologous T-cell therapies, but while their off-the-shelf availability is intriguing, it may be too early to say if their safety and efficacy beats CAR-Ts.
Medicare's CAR-T Policy Should Encompass Future Uses, Sites of Care – BIO
Product developers worry coverage might not extend beyond current indications and use in hospitals, based on the draft national coverage determination released by the Centers for Medicare and Medicaid Services.